Drug Trial Radar · NCT05441488
Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
800
Planned (sponsor's estimate)
Start
Jun 28, 2022
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- AB ScienceIndustry
- Sponsor type
- Industry
- First posted
- Jul 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple sclerosis without relapse.
Conditions
- Progressive Multiple Sclerosis
Interventions
PlaceboDrug
treatment per os
Masitinib (4.5)Drug
Masitinib (titration to 4.5 mg/kg/day)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to confirmed progressionTime frame: 96 weeks
Locations
37 sites in 8 countries. Site status is shown where the registry gives one.
Service de Neurologie Hôpital Henri-Mondor
Créteil, France
Hôpital Roger Salengro
Lille, France
Hôpital Pasteur - CHU de Nice
Nice, France
Centre Hospitalier Universitaire Nimes - Service de Neurologie
Nîmes, France
Centre hospitalier intercommunal de Poissy-Saint-Germain-en-Laye
Poissy, France
Le Centre hospitalier universitaire de Poitiers
Poitiers, France
Centre Hospitalier Universitaire de Rouen
Rouen, France
Centre Hospitalier Universitaire de Strasbourg
Strasbourg, France
Centre Hospitalier Universitaire Toulouse
Toulouse, France
Athens Naval Hospital
Athens, Greece
Eginition Hospital, Athens University Medical School
Athens, Greece
General University Hospital of Larissa
Larissa, Greece
AHEPA University Hospital, Aristotle University of Thessaloniki
Thessaloniki, Greece
Private Clinic ELPIS
Volos, Greece
Azienda Ospedaliero Universitaria Policlinico "G.Rodolico -San Marco"
Catania, Italy
Nzoz Neuro-Medic
Katowice, Poland
NOVI-MED
Ksawerów, Poland
Centrum Neurologii Krzysztof Selmaj
Lodz, Poland
NZOZ Neuro-Med
Lublin, Poland
Generała Jarosława Dąbrowskiego
Oświęcim, Poland
NZOZ Neuro-Kard
Poznan, Poland
Clinical Best Solutions
Warsaw, Poland
State Budgetary Institution of Health of the City of Moscow City Polyclinic #2
Moscow, Russia
Perm Regional Clinical Hospital
Perm, Russia
City Hospital No. 40 Kurortny District
Saint Petersburg, Russia
LLC "Center of socially significant diseases"
Saint Petersburg, Russia
Hospital del Mar
Barcelona, Spain
Hospital Universitario de Cruces
Bilbao, Spain
Gregorio Marañón General University Hospital
Madrid, Spain
Hospital Clínico San Carlos
Madrid, Spain
Hospital Universitario y Politécnico La Fe
Valencia, Spain
Sahlgrenska University Hospital
Gothenburg, Sweden
Centrum för neurologi
Stockholm, Sweden
Lviv Regional Clinical Hospital
Lviv, Ukraine
Rivne Regional Specialized Dispensary for Radiation Protection of the Population Municipal Enterprise
Rivne, Ukraine
Communal Non-Profit Enterprise "Ternopil Regional Clinical Psychoneurological Hospital" of Ternopil Regional Council, Department of Neurology #1
Ternopil, Ukraine
Salutem Medical Center
Vinnytsia, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.